A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Conditions

• Inflammatory Bowel Diseases
• Crohn's Disease

Interventions

• DRUG: Placebo
• DRUG: MORF-057

Sponsor

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)